They are not just a surgical glue, but polymers that can mimic human tissue structure to the point of bonding them without stitches. Tissium, a French startup born from an idea of smart materials, today announced a dual financing: €30 million in equity through a Series D-2 round and a debt facility of up to €30 million from the European Investment Bank (EIB). The underlying technology is called “biomorphic programmable polymers” and works as an adhesive that binds nerves inside tissue, bypassing the need for invasive sutures.

How polymers sew the body back together

The mechanism is as elegant as it is concrete. Tissium’s materials act at the molecular level to restore the integrity of damaged tissue. Once applied, the polymers activate and create a stable bond that reduces trauma to surrounding tissue and speeds recovery. The platform is already used to repair heart defects, hernias and severed nerves.

Two products – one for nerve repair, one for hernia treatment – have received approval from the US Food and Drug Administration, marking the shift from research to commercial stage. CEO and co-founder Christophe Bancel said: “We are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.”

Who invested and why

The €30 million equity round was led by an undisclosed US-based family-owned institutional investor. New family offices, high-net-worth individuals and existing backers such as Mérieux Développement and Cathay joined. In total, Tissium has raised €200 million in equity funding. The EIB debt, of up to €30 million, completes a mixed financial structure focused on commercial growth rather than on experimentation alone.

The funds will finance the rollout of the technology in the United States and support new clinical trials to expand therapeutic indications. The EIB’s involvement is not accidental: it signals a strategic European interest in retaining and scaling deep-tech innovation in healthcare.

Technological sovereignty and smart materials

At a time when medical supply chains show fragility, Tissium’s deal illustrates a European path to health sovereignty. It’s not just about capital: the combination of public research (many polymer skills stem from French institutions) and patient EIB financing creates an ecosystem where advanced materials can turn into regulated, globally distributed products.

From a deployment perspective, the infrastructure of biomorphic polymers does not touch the world of on-premise computing directly. Yet, the growing integration of implantable medical devices with data-monitoring systems raises questions about where and how to manage clinical information. For those designing solutions that combine sensors and smart materials, data residency and GDPR compliance become design levers – a central theme also in local inference of AI models applied to health. AI‑RADAR tracks these intersections between regulation and tech stack, offering analytical frameworks on /llm-onpremise for those evaluating hybrid or fully local architectures.

Tissium shows that a European company can take a radically new material through FDA approval and into commercialization while keeping intellectual property and manufacturing on the continent. The next step will be to see whether the platform can gain market share in the US without diluting its deep-innovation DNA.